help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Szecowka, J.
Right arrow Articles by Efendic, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szecowka, J.
Right arrow Articles by Efendic, S.

Endocrinology, Vol 110, 1268-1272, Copyright © 1982 by Endocrine Society

ARTICLES

Effects of cholecystokinin, gastric inhibitory polypeptide, and secretin on insulin and glucagon secretion in rats

J Szecowka, PE Lins and S Efendic

Pure porcine cholecystokinin-33 [the triacontatriapeptide form of cholecystokinin (CCK-33)], gastric inhibitory polypeptide (GIP), and secretin were infused in rats in doses of 1, 10 and 1000 pmol/kg . min. The peptides were administered alone or in combination with glucose (40 mg/kg . min) or arginine (50 mg/kg . min). In the basal state, CCK-33 and GIP produced significant hypoglycemia at all concentrations used, although they elevated insulin levels only at the highest dose. Secretin had no effect. CCK-33 at a dose of 1 pmol/kg . min enhanced the secretion of insulin induced by glucose or arginine. These effects were more pronounced when higher doses of CCK-33 were administered. GIP at a dose of 1 pmol/kg . min had no effect on insulin release. Higher doses of GIP significantly potentiated insulin release stimulated by glucose or arginine. Secretin (100 pmol/kg . min) had no clear-cut effect on glucose-induced insulin secretion, but it slightly enhanced arginine-induced secretion. All hormones investigated, at all doses used, significantly stimulated the arginine-induced secretion of glucagon. We conclude that CCK-33 is a potent stimulatory factor of glucose- and arginine-induced insulin secretion and should therefore be taken into consideration as an incretin candidate. In addition, CCK-33 and GIP modulate glucose homeostasis by affecting glucagon release.


This article has been cited by other articles:


Home page
 J. Histochem. Cytochem.Home page
E. Bertelli and M. Bendayan
Association between Endocrine Pancreas and Ductal System. More than an Epiphenomenon of Endocrine Differentiation and Development?
J. Histochem. Cytochem., September 1, 2005; 53(9): 1071 - 1086.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. Julien, J. Laine, and J. Morisset
Regulation of Rat Pancreatic CCKB Receptor and Somatostatin Expression by Insulin
Diabetes, June 1, 2004; 53(6): 1526 - 1534.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. Ahrén, J. J. Holst, and S. Efendic
Antidiabetogenic Action of Cholecystokinin-8 in Type 2 Diabetes
J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1043 - 1048.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1982 by The Endocrine Society